Roche’s Tecentriq has been shown to improve survival in non-small cell lung cancer (NSCLC) patients who are not eligible for platinum-based doublet chemotherapy, according to data from the Phase III IPSOS trial. The study, led by University College London (UCL) and supported by Roche, revealed its findings in The Lancet.
The results showed that patients treated with Tecentriq had a median overall survival of 10.3 months, compared to 9.2 months for those receiving standard single-agent chemotherapy. This represents a 22% reduction in the risk of death after treatment with Tecentriq.
Furthermore, after two years, patients treated with Roche's PD-L1 blocker had a survival rate of 24%, while only 12% of chemotherapy-treated patients survived.